NFE2L2 and lung carcinoma: On the other hand, CDO1 might represent a metabolic liability in lung cancers with high intracellular levels of cysteine, especially in the context of NRF2 overactivation that is expected to generate a nutritional phenotype susceptible to therapeutic strategies targeting this vulnerability.